Compugen in the first quarter: cash funds 2029, proof still waits for 2027

Compugen did not publish a quarter that settles the investment debate. It published a quarter that sharpens the waiting period. The balance sheet is still strong, the company has no debt, and management expects cash, deposits and marketable securities to fund operations into 2029 without additional cash inflows. That gives the company real time to reach the MAIA-ovarian interim analysis in the first quarter of 2027, continue the Gilead-partnered Phase 1 trial for GS-0321, and keep exposure to AstraZeneca's external progress with rilvegostomig. But the quarter also shows why time is not proof: $2.2 million of revenue almost exactly matched the reduction in deferred revenue, operating loss widened to $9.0 million, and total cash-related balances fell by about $10.7 million in three months. The current read is therefore mixed but clearer: near-term financing risk is low, clinical and partner execution remain the core risk, and the next reports should be judged less by accounting revenue and more by progress that brings a milestone, clinical data, or a real shortcut to commercial value.

What the company is really selling investors now

Compugen is a clinical-stage biotech, not a recurring-revenue company. Its economics rest on therapeutic discovery and development in immuno-oncology, with four clinical or partnered value centers: internally owned COM701 in the MAIA-ovarian trial, COM902 as the program from which rilvegostomig's TIGIT component is derived, rilvegostomig under AstraZeneca development, and GS-0321 licensed to Gilead and now in a Compugen-run Phase 1 trial. The economic engine is not product sales. It is the ability to turn cash, trials and partnerships into milestones, royalties, or a stronger clinical asset.

That is why this quarter should not be read like a normal earnings quarter. Revenue of $2.2 million does not measure end-market demand, and a $7.7 million net loss is not, by itself, a business failure for a development-stage drug company. The important number is how much time the company has to reach proof before it again depends on capital markets or external cash. On that test, the starting position is better than most clinical biotech stories: $134.9 million of cash, deposits and marketable securities, no debt, and a stated runway into 2029.

Continuity matters here. The prior annual analysis argued that cash bought time but did not remove the burden of proof. The first quarter does not change that sentence. It narrows the margin for error: MAIA is progressing, AstraZeneca is still investing in rilvegostomig, and Gilead remains inside Phase 1, but none of the three channels has yet converted the time bought into new cash or decisive clinical data.

Clinical progress looks active, but the proof point is still far away

The three relevant triggers for Compugen look active rather than dormant. In COM701, the MAIA-ovarian trial is actively enrolling patients across all clinical sites in the United States, Israel and France, and the interim analysis remains on track for the first quarter of 2027. That is the quarter's most important operating datapoint because it links the company's central internal asset to a testable timetable.

In rilvegostomig, AstraZeneca is advancing the asset across 11 ongoing Phase 3 trials, presented clinical and pre-clinical data at AACR 2026, and expects new data at ASCO 2026. For Compugen, this is value exposure that does not require funding the full development burden. It is also value exposure the company does not control. External progress may move market interpretation faster than internal expenses, but shareholders remain dependent on AstraZeneca's decisions, timing and data.

In GS-0321, the Gilead-partnered Phase 1 trial continues to progress as planned. That keeps the partnership alive, but it does not yet improve earnings quality. Until there is a new milestone or another change in Gilead's commitment, the financial impact mainly comes from recognizing deferred revenue. That was the key point in the prior analysis on Gilead revenue quality, and the first quarter makes it even clearer.

Revenue is deferred revenue recognition, not a new cash event

First-quarter revenue was $2.176 million, down 4.7% from $2.284 million in the comparable quarter. The decline is small. The more important point is the source: both first-quarter revenue figures reflected recognition of portions of the upfront payment and IND milestone under the Gilead license agreement. This was not a new product sale or new cash collection during the quarter. It was a gradual release of consideration already sitting on the balance sheet as deferred revenue.

The balance sheet ties the point almost exactly. Total deferred revenue declined from $35.9 million at the end of 2025 to $33.7 million at the end of March 2026, a reduction of $2.176 million, exactly the revenue recognized in the quarter. Within that total, short-term deferred revenue rose from $11.0 million to $11.6 million, while long-term deferred revenue declined from $24.9 million to $22.1 million. This supports the possibility of continued accounting revenue in coming quarters, but it does not prove new cash entering the business.

Gross profit turned positive, at $0.352 million versus a gross loss of $0.116 million in the comparable quarter, mainly because cost of revenue fell faster than revenue. But that improvement is small relative to the expense base. R&D expenses rose 20.2% to $6.937 million, mainly due to MAIA-ovarian clinical expenses and drug supply costs for the trials. Operating loss widened to $9.017 million, and net loss increased to $7.669 million despite $1.353 million of net financial and other income.

That is not automatically negative. In a clinical biotech, higher R&D can be healthy if it advances the central trial. But an investor who reads the revenue line without the deferred-revenue movement may assign too much quality to the quarter. The cash that funds the next stage is on the balance sheet, not in current-period revenue.

Cash funds 2029, and the quarterly decline is the cost of waiting

The all-in cash picture for the quarter includes cash, deposits and marketable securities. It fell from $145.6 million at the end of 2025 to $134.9 million at the end of March 2026, a decline of $10.7 million. The quarterly release does not include a full cash flow statement, so this is not a measure of operating cash flow. It is the total liquidity movement visible from the available balance sheet items.

The decline does not, by itself, break the runway into 2029, but it gives a scale for the cost of time. If similar quarters continue without a new milestone, without clinical data that increases the value of the partnerships, and without a change in the expense pace, the runway will still be long but less comfortable. Compugen's advantage is that there is no debt, so the clock is not a maturity schedule. The drawback is that the next layer of value must come from science and partners, not from deleveraging or existing product sales.

The market layer fits that read. Short interest was 0.06% of float in early May, below the 0.15% sector average, so the stock does not currently look like a crowded short-pressure story. Near-term interpretation is more likely to depend on ASCO updates, MAIA enrollment progress, and any signal from Gilead or AstraZeneca than on another small change in quarterly revenue.

Conclusion

Compugen enters the rest of 2026 with two real advantages: a balance sheet that funds the path to several relatively near proof points, and three clinical or partnered channels that remain active. The first quarter strengthens the view that the company can reach those proof points without an immediate financing need, but it does not improve revenue quality and does not provide new clinical data that warrants a full change in the business read.

The current judgment is a well-funded bridge year, not a breakout year already proven. For the read to improve, MAIA has to reach the interim analysis on time, GS-0321 has to produce evidence that raises Gilead's commitment beyond accounting revenue recognition, and rilvegostomig has to keep producing external progress under AstraZeneca. The read would weaken if liquidity erodes faster, MAIA is delayed, or revenue continues to look good only because deferred revenue is released. That makes the next report's key number not simply net loss, but whether the remaining cash is buying real progress or just more waiting time.